$AMRN Recent Headlines Dow industrials suffer worst drop

New Post Public Reply Private Reply Replies (0) Message Board

Jan 14, 2014 at 11:02 AM

$AMRN Recent Headlines

Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
6 gut checks before the stock market's opening bell 6:12 a.m. July 8, 2013 - Shawn Langlois
6 gut checks before the stock market's opening bell 6:55 a.m. March 27, 2013 - Shawn Langlois
7 gut checks before the stock market's opening bell 7:05 a.m. Feb. 27, 2013 - Shawn Langlois
Friday’s big movers: Groupon soars on Google talk 4:38 p.m. Dec. 7, 2012 - Sue Chang
Amarin down 17% on risks tied to drug launch 8:00 a.m. Dec. 7, 2012 - Steve Gelsi
Amarin down 18% in premarket trades 7:41 a.m. Dec. 7, 2012 - Steve Gelsi
Wednesday’s biggest gaining and declining stocks 3:40 p.m. Oct. 10, 2012 - Sue Chang
Tuesday’s top gaining and declining stocks 3:57 p.m. Sept. 11, 2012 - MarketWatch
Amarin issues patent update on fish-oil drug 11:29 a.m. Sept. 5, 2012 - Val Brickates Kennedy
Amarin jumps 16% after business update 11:06 a.m. Aug. 9, 2012 - Val Brickates Kennedy
Amarin rallies 15% on business update 9:48 a.m. Aug. 9, 2012 - Val Brickates Kennedy
Amarin falls 11% on insider stock-sale reports 11:12 a.m. July 31, 2012 - Val Brickates Kennedy
Amarin, AuthenTec active; advancers outpace decliners 4-1 on NYSE 11:45 a.m. July 27, 2012 - blogs.marketwatch.com
Amarin down 9% in wake of drug approval 9:08 a.m. July 27, 2012 - Val Brickates Kennedy
Amarin gets FDA approval for Vascepa 5:09 p.m. July 26, 2012 - Wallace Witkowski
Amarin: FDA OKs Vascepa for high triglycerides 4:46 p.m. July 26, 2012 - Wallace Witkowski
Amarin halted ahead of FDA decision deadline 2:13 p.m. July 26, 2012 - Val Brickates Kennedy
Amarin halted ahead of FDA decision deadline 2:04 p.m. July 26, 2012 - Val Brickates Kennedy

Stock Watch Monday, 13 January 2014: Intercept Soars As Focus Shifts To Healthcare Market Trends 9:06 a.m. Jan. 13, 2014 - Seeking Alpha
Amarin Out, Intercept Pharma In At J.P. Morgan Healthcare Confab 11:35 a.m. Jan. 12, 2014 - TheStreet.com
While Amarin Continues To Go Rancid, Neptune Will Soar 8:34 a.m. Jan. 11, 2014 - Seeking Alpha
Stock Watch Friday, 10 January 2013: Mannkind Rallies, Sirius Should Satisfy 8:36 a.m. Jan. 10, 2014 - Seeking Alpha
The Twitterverse's Biotech Stock Picks for 2014 8:00 a.m. Jan. 7, 2014 - TheStreet.com
Small Cap BioPharmas With Near Term Catalysts 7:55 a.m. Jan. 3, 2014 - Seeking Alpha
AMRN January 10th Options Begin Trading 11:43 a.m. Jan. 2, 2014 - TheStreet.com
Chelsea: FDA Panel Meeting And Trading Strategies 4:34 p.m. Dec. 30, 2013 - Seeking Alpha
The Billion-Dollar Biotech Club: Speculation Trumped Risk 9:19 a.m. Dec. 30, 2013 - TheStreet.com
Amarin: 3 Things Shareholders Should Demand In 2014 12:13 a.m. Dec. 30, 2013 - Seeking Alpha
Update on Amarin's Vascepa - Analyst Blog 11:15 a.m. Dec. 27, 2013 - Zacks.com
7 Biotechnology Stocks to Sell Now 2:45 a.m. Dec. 25, 2013 - InvestorPlace.com
4 Biotech Stocks on the Move 1:14 p.m. Dec. 20, 2013 - Wall St. Cheat Sheet
FDA Delays Decision on Amarin's Vascepa Drug 11:46 a.m. Dec. 20, 2013 - benzinga.com
Amarin's Anchor Gamble Sends Stock Up 20% On 'No News' News 11:18 a.m. Dec. 20, 2013 - Seeking Alpha
FDA delays ruling on expanding use of Amarin's Vascepa; shares soar 7:25 a.m. Dec. 20, 2013 - Seeking Alpha
Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed 5:03 a.m. Dec. 20, 2013 - benzinga.com
Amarin – Why AMRN Stock Is Set to Open to Sweet 24% Gains 3:12 a.m. Dec. 20, 2013 - InvestorPlace.com
Interesting AMRN Call Options For December 27th 11:24 a.m. Dec. 19, 2013 - TheStreet.com
Amarin's Vascepa: Too Limited A Market Or FDA Blunder? 1:11 p.m. Dec. 18, 2013 - benzinga.com

Equity Technical Dimensions:Seattle Genetics, Amarin, and PerkinElmer 8:00 a.m. Dec. 27, 2013 - PR Newswire
New Drug Application Updates, Appointments, Partnership Programs, and Stock Movements - Research Report on Amarin, Oramed Pharmaceuticals, Synta Pharmaceuticals, Healthways and AMN Healthcare 8:00 a.m. Dec. 25, 2013 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Amarin Corp. plc and Its Board of Directors and of a Lead Plaintiff Deadline of January 3, 2014 3:29 p.m. Dec. 24, 2013 - PR Newswire
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Amarin Corporation plc of Upcoming Deadline 11:27 a.m. Dec. 20, 2013 - BusinessWire
Important Trend Analysis: Amarin Corporation plc, Corporation, Geron Corporation, 3D Systems Corporation 10:22 a.m. Dec. 20, 2013 - ACCESSWIRE
Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed 6:00 a.m. Dec. 20, 2013 - GlobeNewswire
SHAREHOLDER ALERT: Brower Piven Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc Expanding the Class Period to Include July 9, 2009 Through October 16, 2013 and Encourages Investors Who Have Losses in Excess of $150,000 From Investment in Amarin Corporation plc to Inquire About the Lead Plaintiff Position Before the January 3, 2014 Lead Plaintiff Deadline -- AMRN 4:59 p.m. Dec. 19, 2013 - GlobeNewswire
Amarin Announces Leadership Changes 9:07 a.m. Dec. 16, 2013 - GlobeNewswire
Glancy Binkow & Goldberg Files Class Action Lawsuit Against Amarin Corporation 9:32 p.m. Dec. 13, 2013 - BusinessWire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Amarin Corp. plc and Its Board of Directors and a Lead Plaintiff Deadline of January 3, 2014 6:27 p.m. Dec. 11, 2013 - GlobeNewswire
Proposed Offering and Amendments, Patents, Results, and Announcements by Healthcare Companies - Research Report on Forest Laboratories, OncoMed, EnteroMedics, Cadence, and Amarin 8:00 a.m. Dec. 6, 2013 - PR Newswire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
Amarin Announces Notification of Patent Allowances for U.S. Applications 13/685,281, and 13/685,291 Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations 6:00 a.m. Dec. 2, 2013 - GlobeNewswire
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Amarin Corporation plc 9:32 p.m. Nov. 27, 2013 - BusinessWire
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Amarin Corporation, plc and Certain Officers - AMRN 4:56 p.m. Nov. 27, 2013 - PR Newswire
Kantrowitz, Goldhamer & Graifman, P.C. Files Class Action Suit Against Amarin Corporation plc 3:44 p.m. Nov. 27, 2013 - BusinessWire
AAAResearchReports.com Pre-Market Technical Analysis: Elan Corp., Amarin Corp., Cubist Pharmaceuticals, and Seattle Genetics 8:00 a.m. Nov. 27, 2013 - PR Newswire
Bullish Stocks Commentary: Camtek Ltd, Lions Gate Entertainment, ImmunoCellular Therapeutics, Pandora Media, Amarin Corporation 8:47 a.m. Nov. 26, 2013 - PR Newswire
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Amarin Corporation plc 1:32 p.m. Nov. 22, 2013 - BusinessWire
ARIA, MU, AMRN and ARUN added to NASDAQ Active Stock Watch List at EPR 10:19 a.m. Nov. 22, 2013 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Paris Baguette Pioneers Drive-Thru in Oklahoma

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

JOYEE N01 Kicks Off Global Launch with African Orders

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Adding Fireplaces: Home Comfort or Construction Headache?

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...